It may be that Phil King makes his "valuation" based on what he perceives as "similar biotechs" AVH and ARX and therefore thinks he convince the market that PNV should have the same market cap. So he's dedicated to trying to push the share price down to 50c.
His valuation would seem to be at odds with that of MacQuarie for instance, and with PNV delivering growth time is not on his side.
Ann: Director Share Purchase - David Williams, page-21
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
-0.090(3.57%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.50 | $2.43 | $2.311M | 940.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17100 | $2.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 5973 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |